Cognition Therapeutics

Cognition Therapeutics

Yahoo Finance • 20 days ago

Cognition Seures FDA Alignment For Pivotal Phase 3 Trial Of Zervimesine In DLB Psychosis

(RTTNews) - Cognition Therapeutics, Inc. (CGTX) announced that it has reached key alignment with the U.S. FDA on the design of its pivotal Phase 3 study evaluating Zervimesine for psychosis associated with dementia with Lewy bodies (DLB),... Full story

Yahoo Finance • 20 days ago

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeuti... Full story

Yahoo Finance • last month

Cognition Therapeutics Participating in Upcoming Investor Conferences

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciar... Full story

Yahoo Finance • 2 months ago

NanoViricides to Participate at D. Boral Capital Global Conference in NYC

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. D... Full story

Yahoo Finance • 4 months ago

Pre-Market Earnings Report for March 26, 2026 : CMC, DOO, SCVL, DBI, LOVE, LUCD, ABOS, CGTX, RMTI

The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Commercial Metals Company (CMC)is reporting for the quarter ending F... Full story

Yahoo Finance • 4 months ago

3 things to look forward to on Monday

[Historic buildings of Wall Street in the financial district of lower Manhattan, New York City] deberarr U.S. stocks closed lower on Friday and ended lower for a fourth consecutive week as oil sustained higher prices despite efforts to mi... Full story

Yahoo Finance • 7 months ago

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded... Full story

Yahoo Finance • 7 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (th... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president a... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has r... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - PUR... Full story

Yahoo Finance • 10 months ago

Here are the top movers in Monday's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT ATCH [https://www.chartmill.com/stock/quote/ATCH/profile] 148.0% ATLASCLEAR HOLD... Full story

Yahoo Finance • 10 months ago

Which stocks are moving on Monday?

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ATCH [https:... Full story

Yahoo Finance • 10 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘STA... Full story

Yahoo Finance • 10 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously annou... Full story

Yahoo Finance • 11 months ago

Wondering what's happening in today's pre-market session?

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COM... Full story

Yahoo Finance • 11 months ago

Cognition Therapeutics launches $30M share offering

* Cognition Therapeutics (NASDAQ:CGTX [https://seekingalpha.com/symbol/CGTX]) has announced an offering [https://seekingalpha.com/pr/20214045-cognition-therapeutics-announces-30-million-registered-direct-offering-of-common-stock]of 14.7M... Full story

Yahoo Finance • 11 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27,... Full story

Yahoo Finance • 11 months ago

Cognition Therapeutics regains Nasdaq compliance on $1.00 bid price rule

* Cognition Therapeutics (NASDAQ:CGTX [https://seekingalpha.com/symbol/CGTX]) on Tuesday said that it has regained compliance with Nasdaq's minimum bid price requirement. * The biotech firm received the compliance notification from the... Full story

Yahoo Finance • 11 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq L... Full story